Author:
Ueda Kosuke,Maeda Fumiko,Oota Mayumi
Reference17 articles.
1. Nakai Y, Nishimura K, Nakayama M, Uemura M, Takayama H, Nonomura N, Tsujimura A. Weekly, low-dose docetaxel combined with estramastine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol. 2014;19:165–72.
2. Uchida T, Nagata Y, Hyodo T, Saito T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int. 2006;97:56–61.
3. Ueda K, Aoki Y, Hachiya Y. Combination therapy combining low-dose cisplatin and regional hyperthermia for treatment of progressive hormone refractory prostatic carcinoma. Thermal Med. 2007;23:95–100.
4. Ueda K, Maeda F, Hasegawa T, Ito Y: Castration-resistant prostate cancer treated with low -dose chemotherapy and regional hyperthermia for obtaining long survival. Thermal Med 2014;30(Suppl):153.
5. Petrylak DP, Tangan CM, Hussan MHA, Primo NL, Jeffer AJ, Mary ET, Patrick AB, Donna B, Carol M, Manish K, Mitchell CB, Eric JS, Derec R, David C. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.